UNSPSC 51384205: Fenoprofen calcium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C15H13O3.Ca.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0X2CW1QABJ, chemically known as hydratropic acid, m-phenoxy-, (+-)- but more generally known as fenoprofen calcium, which bears US NIH Compound Identifier 3342. European Medicines Agency schedules Fenoprofen calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02120MIG.

Most nations, for tariff and trade purposes, schedule fenoprofen calcium under HS 29189900 and SITC 51396. As of Q4 2014, FENOPROFEN CALCIUM remains US FDA's Preferred Term for this commodity. Fenoprofen calcium bears US NLM identifiers UMLS ID C0887323 and NCI Concept Code C61761. SMILES: CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].O.O.[CA+2].

UNSPSC 51384205 Fenoprofen calcium is a Commodity code that in recent state and local practice encompasses a broader range of pharmaceutical procurement than the code name alone suggests. The three recent opportunities tagged under this code show state and local buying of naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers, and direct-to-manufacturer prescription program capabilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances spanning multiple states (Minnesota Multistate Cooperative Purchasing Alliance administering contracts for Oregon and other participating jurisdictions). The work ranges from tactical procurement of specific volumes for community health initiatives to foundational market research informing future statewide pharmacy benefit strategy.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription contracting capabilities to inform future procurement design, with no formal award value or timeline specified. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, seeking multiple manufacturers to supply generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Vendors on the MMCAP contract must maintain commercial general liability insurance of $5,000,000 per occurrence and comply with cGMP and Drug Supply Chain Security Act requirements.